Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
The Journal of Pharmacology and Experimental Therapeutics|April 15, 2018
Hepatobiliary Disposition of Atovaquone: A Case of Mechanistically Unusual Biliary ClearanceMitesh Patel, Marta Johnson, Caroline J Sychterz, et al.
Molecular Pharmaceutics|February 28, 2009
Biopharmaceutics classification system: validation and learnings of an in vitro permeability assayVictoria E Thiel-Demby, Joan E Humphreys, Lisa A St John Williams, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 4, 2006
In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substratesJarkko Rautio, Joan E Humphreys, Lindsey O Webster, et al.
Toxicology and Applied Pharmacology|December 17, 2009
Toxicity and toxicokinetics of metformin in ratsMichael P Quaile, David H Melich, Holly L Jordan, et al.
Journal of Pharmaceutical Sciences|September 23, 2003
P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamineJoseph W Polli, Todd M Baughman, Joan E Humphreys, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugsKelly M Mahar Doan, Joan E Humphreys, Lindsey O Webster, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 6, 2008
An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)Joseph W Polli, Katie L Olson, John P Chism, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 8, 2012
In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitorMelinda J Reese, Paul M Savina, Grant T Generaux, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 25, 2008
The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactionsJoseph W Polli, Joan E Humphreys, Kelly A Harmon, et al.
British Journal of Clinical Pharmacology|April 24, 2008
The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjectsKimberly K Adkison, Soniya S Vaidya, Daniel Y Lee, et al.
Pageof 6